Compare ACMR & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACMR | AMRX |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.0B |
| IPO Year | 2017 | 2018 |
| Metric | ACMR | AMRX |
|---|---|---|
| Price | $97.82 | $17.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $50.00 | $15.60 |
| AVG Volume (30 Days) | 1.8M | ★ 2.2M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | ★ 0.24 | 0.19 |
| Revenue | ★ $74,643,000.00 | N/A |
| Revenue This Year | $29.37 | $4.48 |
| Revenue Next Year | $23.16 | $7.13 |
| P/E Ratio | $488.79 | ★ $89.37 |
| Revenue Growth | ★ 104.47 | N/A |
| 52 Week Low | $23.03 | $7.67 |
| 52 Week High | $127.19 | $17.86 |
| Indicator | ACMR | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.01 | 74.60 |
| Support Level | $35.32 | $12.46 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 9.85 | 0.55 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 14.28 | 61.74 |
ACM Research Inc supplies capital equipment developed for the semiconductor industry. The company focuses on developing differentiated process solutions that enable effective particle removal, uniform material deposition, and reliable process control for the fabricators of integrated circuits. Its product offerings include wet-cleaning, plating, furnace, PECVD, track, and other front-end processing equipment. Additionally, it develops, manufactures, and sells a range of packaging equipment to wafer assembly and packaging customers. Geographically, the company generates maximum revenue from its customers in Mainland China, and the rest from other regions.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.